Patrick Daly

DocwireNews

In February 2022, the US Food and Drug Administration (FDA) granted <a href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder">accelerated approval</a> for pacritinib (Vonjo) capsules in patients with myelofibrosis and platelet levels below 50 x 109/L.In its phase 3 pivotal trial, <a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384">PERSIST-2</a>, pacritinib was more effective than best available therapy in patients with myelofibrosis and thrombocytopenia. PERSIST-2 randomized 311 patients with myelofibrosis and platelet levels below 100 &times; 109/L to receive pacritinib 400 mg once daily, 200 mg twice daily, or standard care.The researchers concluded that pacritinib significantly improved spleen volume and total symptom reductions compared with conventional therapy (P=.001). The twice-daily dose yielded the greatest improvements in hemoglobin and transfusion dependence and was established as the recommended dose. Notably, pacritinib was effective even among patients who had previously undergone treatment with ruxolitinib.The FDA noted that, as a condition of the expedited approval, studies are ongoing to confirm pacritinib truly yields clinical benefit via its reduction of splenomegaly and symptoms in patients with intermediate- to high-risk primary or secondary myelofibrosis.View More Recent <a href="https://www.docwirenews.com/latest-hematology-oncology-news-2/">Research and Expert Interviews in Hematology and Oncology</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

US FDA Approves JAK2 Inhibitor Pacritinib for Patients With Myelofibrosis

Myelofibrosis

In February 2022, the US Food and Drug Administration (FDA) granted accelerated approval for pacritinib (Vonjo) capsules in patients with myelofibrosis and platelet levels ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe